Imvaria
Healthcare Software · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
441 Palo Alto Ave, Mountain View, Califo...Website
www.imvaria.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About Imvaria
IMVARIA Inc. is a health tech company specializing in AI-driven digital biomarker solutions that enhance clinical decision-making for earlier and more accurate diagnoses of diseases, particularly in lung conditions like idiopathic pulmonary fibrosis (IPF) and interstitial lung disease (ILD). Founded in 2019 by physician-engineers from Google and Stanford University, the company has developed FDA-authorized tools such as Fibresolve and ScreenDx, which provide non-invasive diagnostic support for clinicians. IMVARIA aims to reduce the need for invasive biopsy testing while improving patient outcomes through innovative AI technology. The company serves healthcare professionals, particularly pulmonologists, by offering advanced diagnostic solutions that integrate seamlessly into existing workflows.Explore more
Imvaria Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Imvaria your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Imvaria recently announced quarterly report
Click to see if Imvaria had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Imvaria
Imvaria, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Imvaria launches new products
Website visits: Recent activity has been detected on your website
Check if Imvaria has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Imvaria has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Imvaria is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Imvaria as Masked Content
Find 3 more new buyers
Compare Similar Companies to Imvaria
Compare insights from companies similar to Imvaria, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Imvaria is experiencing very low activity levels compared to other companies in the Software sector.
What does this means?
Imvaria is drawing exceptional interest within the Software industry, suggesting notable developments or strong market momentum, learn more about Imvaria.
Imvaria Tech Stack
A closer look at the technologies used by Imvaria
Imvaria News & Media
IMVARIA Receives 510(k) Clearance for ScreenDx, a First-of-its-Kind Screening Algorithm to Assess for Interstitial Lung Disease
BERKELEY, Calif.--(BUSINESS WIRE)-- #510k--IMVARIA Inc., a health tech company pioneering AI-driven digital biomarker solutions, today announced its second FDA authorization, securing 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its ScreenDx solution, an AI-powered healthcare tool to assist clinicians in assessing for interstitial lung disease (ILD). “ScreenDx is a software‐only device leveraging artificial intelligence to analyze CT imaging data for findings suggestiveIMVARIA Announces FDA De Novo Marketing Authorization of Fibresolve, an AI Biomarker in Lung Fibrosis, and the Adoption of Novel CPT Billing Codes by the American Medical Association
BERKELEY, Calif.--(BUSINESS WIRE)-- #ai--IMVARIA Inc., a health tech company pioneering AI-driven digital biomarker solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted marketing authorization for the use of Fibresolve, a digital biomarker solution that uses artificial intelligence (AI) to guide safe, non-invasive diagnosis of lung fibrosis with a focus on idiopathic pulmonary fibrosis (IPF). This signifies the first ever FDA authorization of a diagnostic toolIMVARIA Enters into Know-how Agreement with Mayo Clinic to Improve the Understanding of Cancer through AI Digital Biomarkers
BERKELEY, Calif.--(BUSINESS WIRE)-- #biomarker--IMVARIA Inc., a health tech company pioneering AI-driven digital biomarker solutions, today announced a collaboration through a know-how agreement with Mayo Clinic to develop AI designed to significantly improve the analysis and understanding of cancer, beginning with lung cancer. With its unique platform built by a cohort of co-founders to include former Googlers, engineers, and medical doctors, IMVARIA’s team of experts specializes in developingIMVARIA Announces Data Demonstrating Company’s Non-Invasive Digital Biomarker for Predicting Mortality in Interstitial Lung Diseases
BERKELEY, Calif.--(BUSINESS WIRE)-- #digitalbiomarker--IMVARIA Inc., a health tech company pioneering AI-driven digital biomarker solutions, today announced data from a study evaluating the company’s lead non-invasive digital biomarker Fibresolve showing the tool’s supplemental ability to predict mortality in patients with interstitial lung disease (ILD). The results will be presented on May 24 as an oral presentation at the Mini Symposium “Looking for the Crystal Ball: Biomarkers to Predict Dis
Read more news
Top Healthcare Software Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Imvaria
Sign Up For FreeTo access detailed company insights
IMVARIA Inc. is a health tech company specializing in AI-driven digital biomarker solutions that enhance clinical decision-making for earlier and more accurate diagnoses of diseases, particularly in lung conditions like idiopathic pulmonary fibrosis (IPF) and interstitial lung disease (ILD). Founded in 2019 by physician-engineers from Google and St... Read More
